Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigilanol tiglate in head and neck squamous cell carcinoma
ACTRN12619001407189Phase 2Terminated
- Sponsor
- QBiotics Group Limited
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of tigilanol tiglate in head and neck squamous cell carcinoma (HNSCC) (3 cohorts), sponsored by QBiotics Group Limited. Primary endpoint: Safety and tolerability of single-dose intratumoral tigilanol tiglate. Started Nov 2019; status: terminated.
02
Drugs
tigilanol tiglate
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ACTRN12619001407189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001407189.